Position: Post-doctoral Associate in Pharmacometrics
Team < Dose individualisation in anticancer drugs > which is a part of the Cancer Research Center of Toulouse (CRCT) INSERM UMR1037, Toulouse University Position description: a one year (renewable), full time, post-doctoral associate position in clinical pharmacokinetics-pharmacodynamics (PK/PD) and quantitative systems pharmacology (QSP). This position focuses on population PK/PD analysis in the area of anticancer therapies. The Post-doc fellow would be invited to get involved in the design, implementation and analysis of clinical trials for drugs developed in Oncology and Haematology. Qualifications required: A solid experience of PK modelling software such as NONMEM, Monolix, R... would be required. The researcher would collaborate on different projects with the other members of our multidisciplinary team (pharmacology, pharmacogenetics, biostatistics, analytical chemistry). The researcher will have access to all the platforms and administrative facilities within the CRCT and will supervise students for master degree placements, or doctoral positions. How to apply: Please send CV, a letter of interest, and the names and email addresses of two referees to Etienne Chatelut (Team leader) chatelut.etie...@iuct-oncopole.fr. CRCT Overview: The brand new 'Oncopole' campus, based in Toulouse (South West of France), gathers academic, scientific, medical, clinical, technological, and pharmaceutical research on cancer. Its missions are to improve fundamental knowledge on all aspects of cancer biology and to provide patients with rapid access to innovative and individualized treatments. The main actors of Toulouse Oncopole are: The Cancer Research Center of Toulouse (CRCT), a public research laboratory supported by Inserm, University Toulouse III-Paul Sabatier and CNRS; The Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), a cancer care center. Oncopole is the place where clinicians from IUCT-O, translational research groups, and basic scientists from CRCT have the ideal environment to develop their projects. The following publications give an idea of our research area: - Schmitt A et al: Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 2010;28:4568-4574 ; - White-Koning M et al: Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011;17:4862-4871 - Thomas F et al : Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther.2016 Feb;99(2):235-42.Chalret du Rieu Q et al: Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Invest New Drugs. 2014;32:985-94. - Imbs DC et al: Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol 2014;73:1189-96.
